BACKGROUND: Perineural invasion (PNI) is the dominant pathway for local invasion in prostate cancer. To date, only few studies have investigated the molecular differences between prostate tumors with PNI and those without it. METHODS: To evaluate the involvement of both microRNAs and protein-coding genes in PNI, we determined their genome-wide expression with a custom microRNA microarray and Affymetrix GeneChips in 50 prostate adenocarcinomas with PNI and 7 without it. In situ hybridization (ISH) and immunohistochemistry was used to validate candidate genes. RESULTS: Unsupervised classification of the 57 adenocarcinomas revealed two clusters of tumors with distinct global microRNA expression. One cluster contained all non-PNI tumors and a subgroup of PNI tumors. Significance analysis of microarray data yielded a list of microRNAs associated with PNI. At a false discovery rate (FDR)<10%, 19 microRNAs were higher expressed in PNI tumors than in non-PNI tumors. The most differently expressed microRNA was miR-224. ISH showed that this microRNA is expressed by perineural cancer cells. The analysis of protein-coding genes identified 34 transcripts that were differently expressed by PNI status (FDR<10%). These transcripts were down-regulated in PNI tumors. Many of those encoded metallothioneins and proteins with mitochondrial localization and involvement in cell metabolism. Consistent with the microarray data, perineural cancer cells tended to have lower metallothionein expression by immunohistochemistry than nonperineural cancer cells. CONCLUSIONS: Although preliminary, our findings suggest that alterations in microRNA expression, mitochondrial function, and cell metabolism occur at the transition from a noninvasive prostate tumor to a tumor with PNI.
BACKGROUND: Perineural invasion (PNI) is the dominant pathway for local invasion in prostate cancer. To date, only few studies have investigated the molecular differences between prostate tumors with PNI and those without it. METHODS: To evaluate the involvement of both microRNAs and protein-coding genes in PNI, we determined their genome-wide expression with a custom microRNA microarray and Affymetrix GeneChips in 50 prostate adenocarcinomas with PNI and 7 without it. In situ hybridization (ISH) and immunohistochemistry was used to validate candidate genes. RESULTS: Unsupervised classification of the 57 adenocarcinomas revealed two clusters of tumors with distinct global microRNA expression. One cluster contained all non-PNI tumors and a subgroup of PNI tumors. Significance analysis of microarray data yielded a list of microRNAs associated with PNI. At a false discovery rate (FDR)<10%, 19 microRNAs were higher expressed in PNI tumors than in non-PNI tumors. The most differently expressed microRNA was miR-224. ISH showed that this microRNA is expressed by perineural cancer cells. The analysis of protein-coding genes identified 34 transcripts that were differently expressed by PNI status (FDR<10%). These transcripts were down-regulated in PNI tumors. Many of those encoded metallothioneins and proteins with mitochondrial localization and involvement in cell metabolism. Consistent with the microarray data, perineural cancer cells tended to have lower metallothionein expression by immunohistochemistry than nonperineural cancer cells. CONCLUSIONS: Although preliminary, our findings suggest that alterations in microRNA expression, mitochondrial function, and cell metabolism occur at the transition from a noninvasive prostate tumor to a tumor with PNI.
Authors: D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: Daniel R Rhodes; Terrence R Barrette; Mark A Rubin; Debashis Ghosh; Arul M Chinnaiyan Journal: Cancer Res Date: 2002-08-01 Impact factor: 12.701
Authors: Gustavo E Ayala; Hong Dai; Rile Li; Michael Ittmann; Timothy C Thompson; David Rowley; Thomas M Wheeler Journal: Prostate Date: 2006-02-15 Impact factor: 4.104
Authors: J E Vivienne Watson; Norman A Doggett; Donna G Albertson; Armann Andaya; Arul Chinnaiyan; Herman van Dekken; David Ginzinger; Christopher Haqq; Karen James; Sherwin Kamkar; David Kowbel; Daniel Pinkel; Lars Schmitt; Jeffry P Simko; Stanislav Volik; Vivian K Weinberg; Pamela L Paris; Colin Collins Journal: Oncogene Date: 2004-04-22 Impact factor: 9.867
Authors: Gustavo E Ayala; Hong Dai; Michael Ittmann; Rile Li; Michael Powell; Anna Frolov; Thomas M Wheeler; Timothy C Thompson; David Rowley Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: Dinesh Singh; Phillip G Febbo; Kenneth Ross; Donald G Jackson; Judith Manola; Christine Ladd; Pablo Tamayo; Andrew A Renshaw; Anthony V D'Amico; Jerome P Richie; Eric S Lander; Massimo Loda; Philip W Kantoff; Todd R Golub; William R Sellers Journal: Cancer Cell Date: 2002-03 Impact factor: 31.743
Authors: Benjamin T Ristau; Jeffrey J Tomaszewski; Yi-Fan Chen; Marnie Bertolet; Elen Woldemichael; Joel B Nelson Journal: World J Urol Date: 2014-11-01 Impact factor: 4.226
Authors: Annika Schaefer; Monika Jung; Kurt Miller; Michael Lein; Glen Kristiansen; Andreas Erbersdobler; Klaus Jung Journal: Exp Mol Med Date: 2010-11-30 Impact factor: 8.718
Authors: A Schaefer; M Jung; G Kristiansen; M Lein; M Schrader; K Miller; A Erbersdobler; C Stephan; K Jung Journal: Urologe A Date: 2009-08 Impact factor: 0.639
Authors: N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef Journal: Br J Cancer Date: 2010-03-30 Impact factor: 7.640
Authors: Neri Mercatelli; Valeria Coppola; Desirée Bonci; Francesca Miele; Arianna Costantini; Marco Guadagnoli; Elena Bonanno; Giovanni Muto; Giovanni Vanni Frajese; Ruggero De Maria; Luigi Giusto Spagnoli; Maria Giulia Farace; Silvia Anna Ciafrè Journal: PLoS One Date: 2008-12-24 Impact factor: 3.240